干扰素和核苷酸类对不同HBV基因型慢性乙型肝炎患者的疗效研究

The treatment effect stuey of Interferon and nudeotides on different HBV genotypes patients with chronic hepatitis B

目的探讨干扰素和核苷酸类对不同HBV基因型慢性乙型肝炎（CHB）患者的疗效。方法对95例CHB患者按基因型和治疗药物的不同分成干扰素B、C型和核苷酸类B、C型共4个组。比较各组治疗前后的血清HBV—DNA含量，丙氨酸氨基转移酶（AIJT），天冬氨酸氨基转移酶（AsT）和总胆红素（TBil）。结果95例HBV—DNA阳性的CHB患者中分为47例B型及48例C型，分剐占49．5％和50．5％。干扰素组25例B型，27例c型；核苷酸类组B型22例，C型21例。在经过12周的早期治疗后，核苷酸类C型组较B型组治疗后的HBV—DNA含量显著性减少（P〈0．01），其余各组问的比较均无统计学意义（P〉0．05）。结论核苷酸类早期治疗C型乙肝病毒感染组效果优于B型组。

Objective To investigate the interferon and nueleotides on the efficacy of different HBV genotypes in patients with chronic hepatitis B （CHB）. Methods 95 eases of CHB patients were divided into 4 groups, interferon type B, interferon type C, nucleotides type B and nucleotides type C, according to genotype and treatment of drug. HBV - DNA, alanine aminotransferase （ ALT）, aspartate aminotransferase enzyme （AST） and total bilirubin （TBil） in serum of each group before and after treatment were compared. Results 95 cases of HBV - DNA positive CHB patients were divided into 47 cases of type B and 48 cases of type C accounted for 49.5 % and 50.5 %. Respectively. 25 cases of type B and 27 cases of type C in the interferon group; 22 cases of type B and 21 cases of type C in the nueleofides group. After 12 weeks of early treatment, HBV- DNA content was lower in nucleotides group C than in group B, significant reduction （P 〈 0.01）, among other groups showed no statistically significant （P 〉 0.05）. Conclusion The early treatment of tvype C in the nuclcotides group is better than type B.